WINTON GROUP Ltd Purchases 329,579 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

WINTON GROUP Ltd raised its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 339.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 426,814 shares of the biopharmaceutical company's stock after purchasing an additional 329,579 shares during the period. WINTON GROUP Ltd owned approximately 0.32% of Dynavax Technologies worth $5,450,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Quest Partners LLC bought a new stake in Dynavax Technologies in the 3rd quarter worth approximately $237,000. Intech Investment Management LLC bought a new stake in shares of Dynavax Technologies in the 3rd quarter worth approximately $416,000. Bank of Montreal Can boosted its stake in shares of Dynavax Technologies by 8.3% in the 3rd quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company's stock valued at $11,848,000 after purchasing an additional 82,449 shares in the last quarter. PDT Partners LLC bought a new position in shares of Dynavax Technologies during the 3rd quarter valued at $3,967,000. Finally, Paloma Partners Management Co purchased a new position in Dynavax Technologies in the 3rd quarter worth $280,000. Institutional investors own 96.96% of the company's stock.

Dynavax Technologies Trading Down 5.1 %

NASDAQ:DVAX traded down $0.70 during mid-day trading on Monday, reaching $12.99. 752,564 shares of the company's stock traded hands, compared to its average volume of 2,154,067. The company has a 50 day moving average price of $13.35 and a 200-day moving average price of $12.51. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of 72.14 and a beta of 1.23. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. Dynavax Technologies Co. has a 12-month low of $9.74 and a 12-month high of $14.63.

Remove Ads

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.05. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The firm had revenue of $72.03 million for the quarter, compared to analysts' expectations of $72.70 million. On average, sell-side analysts predict that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on DVAX. StockNews.com raised Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Monday, February 24th. The Goldman Sachs Group cut Dynavax Technologies from a "neutral" rating to a "sell" rating and decreased their price target for the stock from $15.00 to $12.00 in a research note on Tuesday, February 11th. William Blair reissued an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 21st. Finally, HC Wainwright restated a "buy" rating and issued a $31.00 target price on shares of Dynavax Technologies in a report on Friday, February 21st.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.